Northwest Biotherapeutics, Inc. (BST:NBYB)

Germany · Delayed Price · Currency is EUR

0.184

-0.001 (-0.54%)

At close: Dec 5, 2025

-25.81% (1Y)

Market Cap	312.66M
Revenue (ttm)	798.61K
Net Income (ttm)	-77.75M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,500
Average Volume	15,820
Open	0.190
Previous Close	0.185
Day's Range	0.184 - 0.190
52-Week Range	0.170 - 0.450
Beta	n/a
RSI	40.34
Earnings Date	Nov 13, 2025

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1996

Employees 25

Stock Exchange Stuttgart Stock Exchange

Ticker Symbol NBYB

Full Company Profile

Financial Performance

In 2024, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -28.47% compared to the previous year's $1.93 million. Losses were -$85.19 million, 32.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.